Norfolk research company plans clinical trials using medical marijuana


Eight months after receiving a broad federal license for importing
medical cannabis
, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions.

Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer. The new venture potentially opens the door to significantly expanding national research being done on the medical benefits of cannabis.

It brings the company one step away from its main focus: pharmaceutical drug screening through preclinical trials of liver diseases, obesity and diabetes. But Rebecca Caffrey, co-founder and CEO of Sanyal, said the research possibilities with cannabis extracts are endless.